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Macrophages frequently infiltrate tumors and can
enhance cancer growth, yet the origins of the macro-
phage response are not well understood. Here we
address molecular mechanisms of macrophage
production in a conditional mouse model of lung
adenocarcinoma. We report that overproduction of
the peptide hormone Angiotensin II (AngII) in tumor-
bearing mice amplifies self-renewing hematopoietic
stem cells (HSCs) and macrophage progenitors. The
process occurred in the spleen but not the bone
marrow, and was independent of hemodynamic
changes. The effects of AngII required direct
hormone ligation on HSCs, depended on S1P1
signaling, and allowed the extramedullary tissue
to supply new tumor-associated macrophages
throughout cancerprogression.Conversely, blocking
AngII production prevented cancer-inducedHSCand
macrophage progenitor amplification and thus
restrained the macrophage response at its source.
These findings indicate that AngII acts upstream of
a potent macrophage amplification program and
that tumors can remotely exploit the hormone’s
pathway to stimulate cancer-promoting immunity.
INTRODUCTION
Macrophages are tissue-resident white blood cells that protect
against infection and injury. Some macrophages, however,
inversely affect prognosis by contributing to cancer. Macro-
phages that infiltrate the tumor stroma are often referred to as
tumor-associated macrophages (TAMs). Experimental models
using mice have shown that TAMs can facilitate tumor progres-
sion by promoting inflammation, stimulating angiogenesis,
enhancing tumor cell migration andmetastasis, and suppressing
antitumor immunity (De Palma et al., 2007; Mantovani et al.,
2008; Grivennikov et al., 2010; Qian and Pollard, 2010; Hanahan296 Immunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc.and Coussens, 2012). Clinical studies have further reported that
the presence of TAMs correlates with adverse outcome and
shorter survival in various cancer types, including non-small-
cell lung cancer (NSCLC) (Zhang et al., 2011a; Zhang et al.,
2011b), breast cancer (DeNardo et al., 2011), and Hodgkin’s
lymphoma (Steidl et al., 2010). TAMs are often the most
abundant host cell population within the tumor stroma, but
because they are short-lived and do not proliferate in situ,
TAMs must be continuously replaced throughout cancer
progression (Sawanobori et al., 2008; Movahedi et al., 2010;
Cortez-Retamozo et al., 2012).
Inflammatory tissue macrophages descend from circulating
monocytes, which are initially produced in bone marrow by
hematopoietic stem cells (HSCs) (van Furth and Cohn, 1968;
Geissmann et al., 2010). These macrophages are distinct from
Myb-independent macrophages that develop in the embryo
before the appearance of HSCs (Schulz et al., 2012). Monocyte
production by HSCs involves the generation of discrete cell
progenitor intermediates, including macrophage and dendritic
cell progenitors (MDPs) (Fogg et al., 2006). These hematopoietic
stem and progenitor cells (HSPCs) can divide, whereas mono-
cytes and macrophages typically do not (van Furth and Cohn,
1968). Thus, the prevailing model of macrophage response
implies that fundamental amplification and differentiation occur
in the bone marrow.
Despite the prevalence of this linear model of macrophage
production, HSPCs constitutively exit the bone marrow
(Goodman and Hodgson, 1962; Wright et al., 2001) and, during
inflammation, support myelopoiesis in extramedullary tissue
(Massberg et al., 2007). The spleen’s red pulp can be a site of
HSPC activity during disease in both humans and mice
(Freedman and Saunders, 1981; Cortez-Retamozo et al., 2012;
Dutta et al., 2012). The newly produced cells supplement
a reservoir of splenic monocytes (Swirski et al., 2009), which
are readily mobilized to contribute large numbers of macro-
phages to distant lesions. This process occurs after myocardial
infarction (Leuschner et al., 2012) and during the progression of
atherosclerosis (Robbins et al., 2012) and cancer (Cortez-
Retamozo et al., 2012). Although the bone marrow maintains
the monocyte repertoire in steady state, the monocyte produc-
tion can be outsourced during inflammatory diseases.
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generation of cells with heightened tumor-promoting functions
(Cortez-Retamozo et al., 2012; Ugel et al., 2012); however, the
molecular mechanisms that drive such response remain largely
unknown. We investigated the macrophage response by using
a conditional genetic mouse model of lung adenocarcinoma
(hereafter referred to as KP). This model produces autochtonous
tumors from a few somatic cells via Cre-recombinase activation
of oncogenic Kras and inactivation of p53 (DuPage et al., 2009).
Tumors in KPmice present genetic alterations that are frequently
found in the human disease, progress to high-grade tumors, and
are chronically infiltrated by tumor-promoting macrophages. KP
mice thus provide an opportunity to study the macrophage
response under in vivo conditions that mirror central aspects of
the human disease. Our KP mice studies showed that increased
AngII augments the production of splenic HSPCs and conse-
quently facilitates TAM supply from extramedullary tissue
throughout cancer progression.
RESULTS
AngII Amplifies HSCs and Macrophage Progenitors
in the Spleen
We investigated AngII because it interacts with mononuclear
phagocytes and promotes inflammation (AbdAlla et al., 2004;
Lanz et al., 2010; Ma et al., 2012), and because it is found at
increased concentrations in the plasma of lung-tumor-bearing
KP animals as compared to age-matched tumor-free controls
(Figure 1A). AngII is known to release monocytes from their
splenic reservoir (Swirski et al., 2009; Shi and Pamer, 2011)
and therefore may not be involved in de novo mononuclear
phagocyte production. Yet splenocytes obtained from mice
infused for 1 week with AngII showed elevated colony-forming
unit-macrophage (CFU-M) activity in vitro (Figures 1B and 1C).
These tumor-free mice received AngII continuously via osmotic
mini-pumps at a dose that replicated the plasma concentration
found in tumor-bearing mice (Figure 1A). AngII-treated mice
and tumor-bearing KP mice showed comparable splenic
CFU-M activity (Figures 1B and 1C). These data led us to
consider that AngII may drive splenic macrophage progenitor
amplification.
To address AngII’s role in amplifyingmacrophage progenitors,
we quantified HSPCs ex vivo by flow cytometry in various
mouse cohorts. The analyses confirmed a marked increase in
total number of splenic Linlo CD117+ Sca-1+ HSCs and Linlo
CD117+ Sca-1 CD115+ CD16/32+ CD34+ MDPs in AngII-
treated mice as compared to control mice (9 ± 1- and 25 ± 4-
fold increase for HSCs and MDPs, respectively; Figure 1D, see
also Figure S1A available online). We observed similar splenic
HSC and MDP responses in tumor-bearing KP mice (HSCs:
7 ± 2-fold increase in KP mice compared to control tumor-free
mice; MDPs: 20 ± 6-fold increase). These responses remained
detectable at week 21 after tumor initiation (Figure S1B).
AngII-treated mice (Figure 1E) and KP tumor-bearing mice
(data not shown) also expanded splenic common myeloid
progenitors (CMPs) and granulocyte macrophage progenitors
(GMPs), which are cell intermediates that derive from HSCs
and produce MDPs. AngII infusion did not seem to affect other
splenic lineages in this experimental setting (Figure 1D). Theamplification of HSCs, CMPs, GMPs, and MDPs occurred in
the spleen but not in bone marrow (Figures 1D and 1E). Finally,
these cell populations were not amplified in the spleens of
control mice that received osmotic mini-pumps delivering PBS
only (Figure 1E). Thus, AngII alone is sufficient to trigger extrame-
dullary macrophage progenitor amplification as found in tumor-
bearing KP mice.
AngII Amplifies HSCs and Macrophage Progenitors
Regardless of Hemodynamics
Tumor development in KP mice did not measurably alter blood
pressure (Figure S1C), suggesting that increased AngII levels
in these mice did not alter hemodynamics. Nevertheless,
because AngII is a known vasoconstrictor, we measured its
capacity to induce hematopoietic progenitor cell expansion
in the presence of the vasodilator hydralazine. Both AngII
and hydralazine were continuously released by osmotic mini-
pumps implanted separately in the same animals. Hydralazine
treatment reduced systolic and diastolic blood pressures as
expected (from 120 ± 14/91 ± 16 to 99 ± 9/65 ± 15 mmHg,
mean ± SD); however, it did not alter splenic HSC/MDP amplifi-
cation (Figure 1D). Thus AngII triggers a splenic HSC and
macrophage progenitor response independently from its effects
on hemodynamics.
Direct AngII-AGTR1A Signaling on HSCs
and Macrophage Progenitors
Based on the above results, we investigated whether the
hormone acts directly on hematopoietic cells. To test this
hypothesis, we first generated mouse chimeras in which expres-
sion of the AngII receptor, AGTR1A, was restricted to either
hematopoietic or nonhematopoietic cells (Figure 2A) and then
measured the AngII’s capacity to amplify HSCs and MDPs in
these mice. The experiments showed that the splenic response
depended strictly on AngII-AGTR1A signaling in hematopoietic
cells (Figure 2B). Furthermore, splenic HSCs and MDPs were
amplified equally in mice with Agtr1a–/– or Agtr1a+/+ nonhemato-
poietic cells (Figure 2B), indicating that AngII-AGTR1A signaling
in nonhematopoietic cells did not influence the hematopoietic
response.
In a second approach, we tracked Agtr1a+/+ and Agtr1a–/–
(EGFP+) HSCs following adoptive transfer into wild-type mice
that were infusedwith AngII. Intravital microscopy of the spleen’s
red pulp (Pittet and Weissleder, 2011) indicated that donor
Agtr1a–/– HSCs failed to produce splenic colonies in vivo as
compared to their Agtr1a+/+ counterparts (Figures 2C and 2D;
Figure S2). This impairment was not due to an intrinsic prolifera-
tive and/or survival defect of Agtr1a–/– HSCs because both
Agtr1a–/– and Agtr1a+/+ HSCs were equally able to proliferate
and produce colonies in vitro (Figure 2E), and the few Agtr1a–/–
HSCs that accumulated in splenic tissue produced colonies
that were comparable in average size to the ones produced by
Agtr1a+/+ cells (Figure 2F).
Finally, we used flow cytometry to investigate the fate of
transferred HSCs in recipient mice exposed to AngII. In these
experiments, HSCs and recipient mice were either Agtr1a–/–
or Agtr1a+/+ (Figure 2G). Donor Agtr1a–/– HSCs failed to
produce monocytic cells (defined as CD11b+ Ly-6Chi [B220,
CD19, CD90.2, DX5, NK1.1, Ly-6G, F4/80, CD11c]lo), whereasImmunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc. 297
Figure 1. AngII Amplifies HSC and Macrophage Progenitors in the Spleen Regardless of Hemodynamics
(A) AngII concentration in plasma (measured by ELISA) from control mice (n = 9), mice with KP tumors at 11–12 weeks post tumor initiation (n = 12) and mice
infused with AngII via an osmotic mini-pump (n = 6).
(B) Number of CFUs obtained with total splenocytes from control mice (n = 3), mice with KP tumors (n = 3), and mice infused with AngII (n = 4).
(C) Representative photograph of CFUs obtained with splenocytes from a mouse infused with AngII. Scale bar represents 1 mm.
(D) Fold increase in the number of HSCs (top), MDPs (middle), and Lin+ cells (down) in bone marrow (white circles) and spleen (gray circles) of KP mice (n = 27),
mice with AngII pump (n = 6), and mice with AngII and hydralazine pumps (n = 5), when compared to untreated control mice (average from n = 5–12). (Lin defined
as [B220/CD19/CD90.2/DX5/NK1.1/Ly-6G]).
(E) Quantification of HSCs, CMPs, GMPs, and MDPs in the bone marrow (left) and spleen (right) of mice that were left untreated (control, n = 5), that received
a mini-pump delivering PBS for 8 days (PBS pump, n = 5), and that received a mini-pump delivering AngII for 8 days (AngII pump, n = 5).
Data in (A), (B), and (E) are presented as mean ± SEM. Data in (D) indicate measurements for single mice. *p < 0.05; ns, nonsignificant. See also Figure S1.
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even in Agtr1a–/– recipient animals. From these experiments,
we concluded that: (1) HSCs sense AngII directly, (2) the HSC298 Immunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc.response does not depend on AngII-AGTR1A signaling in nonhe-
matopoietic cells, and (3) this sensing mechanism amplifies
a macrophage progenitor response in vivo.
Figure 2. AngII Amplifies HSCs and Macrophage Progenitors via Direct Signaling through the AGTR1A Receptor
(A) Cartoon depicting the generation of three different bone marrow chimeras and their use in experiments. #1 shows that reconstituted mice express the Agtr1a
receptor on hematopoeitic cells (HC) and on non-HC; #2 shows that reconstituted mice express the Agtr1a receptor on non-HC only, and #3 shows that
reconstituted mice express the Agtr1a receptor on HC only. All mice were challenged with AngII in vivo (delivered via a mini-pump) before examination of the
hematopoietic response.
(B) Fold increase in the number of splenic HSCs (top) and MDPs (bottom) in AngII-treated mice in groups #1, #2, and #3 (as described in A; n = 3–4) and when
compared to untreated control mice (average from n = 4).
(C) Intravital micrographs of the splenic red pulp from mice that received Agtr1a+/+ (top) or Agtr1a–/– (bottom) EGFP+ HSCs. Left image on top shows Agtr1a+/+
HSC-derived cell clusters at higher magnification. Venous sinuses are in red. Data are representative of two mice per condition analyzed. Scale bar represents
1 mm.
(D) Number of EGFP+ clusters per mm2 of splenic tissue from mice described in (C).
(E) Fold expansion of Agtr1a–/– and Agtr1a+/+ HSCs in vitro upon culture for 3 days in complete HSC medium.
(F) Size of EGFP+ clusters in splenic tissue from mice described in (C).
(G) Tracking of monocyte-derived HSCs in vivo. Recipient mice were exposed to AngII and received an i.v. injection of EGFP+ HSCs. The monocyte progeny was
quantified 5 days later by flow cytometry. Donor HSCs and recipient mice were either Agtr1a–/– or Agtr1a+/+ as indicated.
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ns, nonsignificant.
See also Figure S2.
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Figure 3. AngII Signaling Retains HSCs in the Spleen in a S1P1-Dependent Manner
(A) Percent of bonemarrow (left) and splenic (right) HSC andMDPpopulations in S/G2 phase of the cell cycle. Cells were obtained frommice treated (+AngII, n = 4)
or not (Control, n = 3) with AngII for 1 week, stained with DAPI ex vivo, and analyzed immediately by flow cytometry.
(B) Percent chimerism of splenic HSCs in mice parabiosed for 14 days, with each of the parabionts either infused, or not, with AngII. Data show chimerism at the
time of separation (0 hr, n = 2) and 1 day later (24 hr, n = 4).
(C) Percent chimerism of splenic HSCs in mice parabiosed for 30 days, with each of the parabionts bearing KP tumors (+ KP cancer) or not (–KP cancer). Data
show chimerism at the time of separation (0 hr, n = 4) and 1 d later (24 hr, n = 4).
(D) Relative S1p1mRNA content in splenic HSCs (left) andmacrophage progenitors (right) obtained fromAgtr1a+/+ orAgtr1a–/–mice. Mice were exposed or not to
AngII in vivo for 1 week, as indicated, and analyzed immediately ex vivo (n = 6–7). Values are normalized to S1p1 mRNA expression in wild-type cells obtained
from untreated mice (average from n = 6).
(E) Relative S1p1mRNA expression levels in Agtr1a+/+ (left) and Agtr1a–/– HSCs analyzed immediately (0 hr, n = 2) and after 24 hr in medium supplemented with
10 mM AngII (24 hr AngII, n = 3); or after 24 hr in medium alone (24 hr medium, n = 3).
(F) Ex vivo chemotactic index of splenic Lin CD117+ progenitor cells toward an S1P gradient. Cells were obtained from mice exposed, or not, to AngII in vivo
(n = 4). (Lin defined as [B220/CD19/CD90.2/DX5/NK1.1/Ly-6G/CD11b/CD11c]).
(G) Accumulation of splenic HSCs in animals that received i.p. injections of PBS (–FTY720) or FTY720 (+FTY720) for 7 consecutive days (n = 5).
(H) Procedure used to coinject equal numbers of S1p1norm and S1p1const HSC populations. The progeny of each HSC population was evaluated 7 days later.
(I) Detection by flow cytometry of the progeny of CD45.2 S1p1norm and CD45.1 S1p1const HSCs. HSC-derived monocytes were defined as CD11b+ Lin
[F4/80/ CD11c]lo Ly-6Chi EGFP+ (Lin: [B220/ CD19/ CD90.2/ DX5/ NK1.1/ Ly-6G]).
(J) Quantification of S1p1norm and S1p1const HSC-derived monocytes (n = 8) in mice described in (I).
(legend continued on next page)
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We considered that the hormone might amplify splenic HSCs
and macrophage progenitors by inducing them to proliferate;
however, analyses conducted both ex vivo (Figure 3A) and
in vitro (Figure S3A) excluded this possibility. Alternatively, the
hormone could retain HSPCs that travel through extramedullary
tissue (Wright et al., 2001). To test this hypothesis, we estab-
lished parabiosis between twoAngII-infusedmice (or two control
mice) until splenic HSC equilibration (Massberg et al., 2007) and
then measured chimerism of parabiont-derived splenic HSCs
after separating the parabionts. The separation prevents further
cell exchange between animals; thus, new cells that accumulate
in the spleen predominantly originate from the host, and the rela-
tive amount of parabiont-derived HSCs that remain in the tissue
indicates their residence time (Liu et al., 2007). This experimental
approach showed that exposure to AngII significantly increases
the retention of HSCs in the spleen (Figure 3B). We then investi-
gated splenic HSC retention in tumor-bearing KP mice. This
involved parabiosis between two KP mice (or two control mice)
and measuring chimerism by using the method detailed above.
This experiment further indicated that KP cancer increases
splenic HSC retention (Figure 3C). We thus concluded that
both AngII and cancer alter splenic HSC trafficking in vivo.
AGTR1A Ligation Alters S1P1 Signaling in HSCs
Our next goal was to define how AngII signaling favors retention
of HSCs and macrophage progenitors in the spleen. We investi-
gated signaling through sphingosine-1-phosphate receptor 1
(S1P1, also referred to as S1PR1) because this Gai-coupled
receptor is known to promote HSC recirculation (Massberg
et al., 2007). We confirmed that HSCs and macrophage progen-
itors––but not monocytes––expressed S1p1 at detectable levels
in steady state (Figure S3B); however, these cells strongly
repressed S1p1 expression in mice exposed to AngII (Figure 3E).
Furthermore, HSCs failed to downregulate S1p1 expression in
Agtr1a–/– mice exposed to AngII in vivo (Figure 3D), and purified
HSCs subjected to AngII in vitro downregulated S1p1 only if they
expressed AGTR1A (Figure 3E). These findings indicate that
AngII-mediated repression of S1p1 in HSCs requires direct
signaling through the AGTR1A receptor.
In accordance with the above findings, we found that splenic
progenitors obtained from AngII-infused mice (i.e., cells that
had downregulated S1p1 expression in vivo) lost their ability to
migrate toward an S1P gradient ex vivo (Figure 3F). Control
experiments showed that the same cells remained capable of
migrating toward the cytokine SDF-1a and thus remained bio-
logically active (Figure S3C). Also, in vivo administration of the
small-molecule inhibitor FTY720, which impairs S1P sensing
by S1P1 (Schwab and Cyster, 2007), was sufficient to promote
the accumulation of HSCs in the spleen (Figure 3G).
We then assessed whether the splenic hematopoietic
response mediated by AngII indeed depends on S1P1 signaling.
To this end, we engineered both S1p1const CD45.1+ EGFP+
HSCs (i.e., HSCs that expressed S1P1 constitutively and were(K) Relative S1p1 mRNA content in splenic progenitors obtained from tumo
(KP, n = 10), KP mice that were treated with enalapril for 12 days (KP + enalapril,
n = 4).
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ns, nonsignificant. Setracked according to CD45.1 and EGFP expression) and
S1p1norm CD45.2+ EGFP+ HSCs (i.e., HSCs that could downre-
gulate S1P1 normally and were tracked according to CD45.2
and EGFP expression). We used a competitive assay to test
these twoHSCpopulations’ capacity to producemonocytic cells
in response to AngII in vivo. Specifically, equal numbers of the
two HSC populations were coinjected into EGFP recipient
mice, which were infused with AngII. The monocyte progeny of
donor EGFP+ HSCs were analyzed 7 days later by flow cytome-
try (Figure 3H). S1p1norm HSC-derived monocytes outnumbered
their S1p1const counterparts by4:1, indicating that AngII-medi-
ated S1p1 downregulation in HSCs directly amplifies monocytes
in vivo (Figures 3I and 3J).
Splenic HSCs decreased S1p1 expression in tumor-bearing
KP mice as expected (Figure 3K); however, administering either
the AGTR1A antagonist losartan or the Angiotensin converting
enzyme inhibitor enalapril (used to decrease AngII levels) pre-
vented thisprocess (Figure3K).Basedon thesefindings,we inves-
tigated whether reducing AngII production in KPmice by injecting
enalapril could prevent cancer-induced HSC and macrophage
progenitor amplification and thus restrain the TAM response.
Blocking AngII Production Impairs the TAM Response
at Its Source
Initially, we analyzed KP mice at 12 weeks after tumor initiation
and 5 days after reducing AngII production with enalapril (Fig-
ure 4A). In this experimental setting, temporarily interrupting
AngII production did not detectably affect tumor burden (data
not shown) but did restrain the amplification of splenic HSCs
and HSC-derived MDPs, monocytes, and lung macrophages
(Figure 4B). Lung macrophages were defined as F4/80+ [B220,
CD19, CD90.2, DX5, NK1.1, Ly-6G]/lo. These cells express
CD11b at varying levels (Cortez-Retamozo et al., 2012).
In a second approach, we transferred donor EYFP+ hemato-
poietic progenitor cells into cohorts of recipient animals in order
to evaluate the capacity of a discrete cell population to produce
TAMs in different in vivo conditions (Figure 4C). Analysis by flow
cytometry on day 5 posttransfer showed that donor progenitor
cells produced splenic monocytes and TAMs in tumor-bearing
KP mice, as expected (Figure 4D). However, enalapril adminis-
tration in KP mice decreased the production of these cells to
levels found in tumor-free controls (Figure 4D).
We further investigated enalapril’s impact on the TAM
response by artificially limiting the drug’s action to the spleen.
Specifically, EYFP recipient KP mice (not treated with enalapril)
received spleens transplanted from EYFP+ KP donor mice, some
of which that were previously treated with enalapril (Figure 4E).
The procedure allowed us to track EYFP+ splenocytes that relo-
cated into the recipient (Swirski et al., 2009). Donor spleens were
extensively perfused before transplantation to avoid exposing
recipient mice to the drug. Analysis at 24 hr posttransplantation
showed that enalapril-treated spleens contributed significantly
fewer EYFP+ TAMs than their control counterparts (Figure 4F).
Taken together, the above findings indicate that short-termr-free mice (control, n = 10), KP mice at weeks 12 post tumor initiation
n = 10), and KP mice that were treated with losartan for 7 days (KP + losartan,
e also Figure S3.
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Figure 4. Reduction of AngII Production
Impairs the TAM Response at Its Source
(A) Procedure used to measure the effects of
short-term enalapril administration on splenic and
lung responses in mice treated or not for 5 days
with enalapril (treatment was initiated 12 weeks
post tumor initiation). Age-matched, tumor-free
untreated mice served as controls.
(B) Quantification of splenic HSCs, MDPs, mono-
cytes, and lung macrophages in the cohorts of
mice described in (A) (nR 4).
(C) Procedure used to track the progeny of EYFP+
myeloid progenitor cells that were transferred into
mice with or without lung cancer (±AdCre infec-
tion) and treated or not with enalapril. The EYFP+
progenitor cells were injected 11 weeks post
tumor initiation. The progeny of these cells was
evaluated in bonemarrow, spleen, and lung 5 days
later.
(D) Number of EYFP+ myeloid progenitor-derived
monocytes (in bone marrow and spleen) and
macrophages (in lungs) in mice described in (C)
(n = 6–7).
(E) Procedure used to transplant spleens from
donor KP mice (treated or not with enalapril) into
recipient KP mice (not treated with enalapril).
(F) Left: flow cytometry histogram profiles show
donor spleen-derived EYFP+ TAMs that accumu-
lated in the lungs of recipient KP mice (experi-
mental procedure described in E). The trans-
planted spleens were obtained from mice that
were previously treated or not with enalapril
(±enalapril [donor]). Right: quantification of EYFP+
TAMs derived from donor spleens that were treated (white bars) or not (black bars) with enalapril. Recipient mice were sacrificed and analyzed 1 day post
transplantation (n = 2).
Data in (B) are presented as mean ± SEM. Data in (D) are presented as median with dots indicating measurements for single mice. *p < 0.05; **p < 0.01; ns,
nonsignificant. See also Figure S4.
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cation in the spleen. Furthermore, enalapril treatment likely did
not trigger direct anti-tumor effects in KP mice because tumor
cells derived from these mice remained fully able to expand in
presence of high dose enalapril in vitro (Figure S4).
Prolonged Reduction of AngII Production Restrains
TAMs and Increases Survival
Following the short-term results reported above, we investigated
the impact of uninterrupted, extended enalapril treatment of KP
mice. KP mice received daily enalapril over 3 weeks starting at
week 8 after tumor initiation. This dose is well tolerated in vivo
(Leuschner et al., 2010). Controls included untreated KP mice,
KP mice that received hydralazine (to monitor the effects of
low blood pressure triggered by enalapril treatment), and
tumor-free controls. Evaluation in week 11 showed that enalapril
treatment restrained tumor-induced HSC andMDP responses in
the spleen but not in bone marrow, whereas treatment with
hydralazine had no effect (Figure 5A). Enalapril, but not hydral-
azine, also compromised downstream monocyte amplification
in the spleen and macrophage accumulation in the lungs (Fig-
ure 5B; Figures S5A and S5B).
The lung macrophage repertoire comprises cells that derive
from HSC-independent precursors (Schulz et al., 2012) and
Ly-6Clo monocytes (Landsman et al., 2007)––these macro-302 Immunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc.phages are found already in steady-state––as well as Ly-6Chi
monocytes that accumulate in diseased lung during tumor
development. Accordingly, lung macrophages were qualitatively
different in tumor-bearing and tumor-freemice (Figure 5C). Over-
expression of several of the transcripts found at higher levels in
macrophages from tumor-bearing mice is associated with the
acquisition of tumor-promoting functions (Gabrilovich et al.,
2012). Treatment of tumor-bearing mice with enalapril largely
restored the lung macrophage phenotypes to that observed in
tumor-free mice (Figure 5C). These results suggest that enalapril
treatment in KP mice prevents accumulation of Ly-6Chi mono-
cyte-derived, tumor-promoting macrophages.
To evaluate the impact of enalapril and hydralazine on tumor
progression, we used high-resolution computed tomography
(CT) to image the lungs of KP mice 11 weeks after tumor induc-
tion (i.e., 3 weeks after starting enalapril or hydralazine
treatments). This experiment showed that enalapril treatment
restrained the number of detectable lung tumor nodules and total
lung tumor volumes in the majority of mice analyzed, whereas
control mice treated with hydralazine showed full-fledged tumor
progression (Figures 5D and 5E). Histopathological analysis on
week 11 confirmed that enalapril treatment reduced cancer
growth (Figure S5C).
Next we performed a 30-week longitudinal study to compare
the survival of KP mice that received either no treatment or
Immunity
Macrophage Production Mediated by Angiotensin IIenalapril alone. Kaplan-Meier analysis indicated that treatment
with 50 mg/kg enalapril increased survival (p = 0.0038, Mantel-
Cox test; Figure 5E). The phenotype was preserved in a separate
experiment in which mice received a lower dose of enalapril
(5 mg/kg; p = 0.031, Mantel-Cox test). Collectively, these find-
ings indicate that targeting the AngII pathway restrains macro-
phage progenitor amplification, reduces the number of TAMs,
and provides therapeutic benefit in the KP mouse model.
AGT Overexpression in Mouse and Human NSCLC
To begin to explore what mechanisms control AngII production
in KP mice, we examined expression levels of angiotensinogen
(Agt), the AngII precursor normally produced in the liver. Interest-
ingly, we found significant Agt overexpression in the lungs of
tumor-bearing mice (6.6 ± 1.8 mean fold increase when
compared to control lungs). Agt expression was selectively
increased in tumor-involved regions, both at transcript (Fig-
ure 6A) and protein (Figure 6B) levels. Analyzing tumor stroma
cell fractions (tumor cells, macrophages, and others) suggested
that tumor cells are a major source of Agt (Figure S6A). We
confirmed that Agt was produced by at least some carcinoma
cells: 4 out of 13 tumor cell lines derived from KP tumor nodules
still overexpressed Agt in vitro (Figure S6B). By comparison,
other candidate factors that may influence the macrophage
response (Csf1, Csf2, Ifng, Il1b, and Tnfa) did not detectably
increase in tumor-involved regions (Figure S6C). KP tumor
nodules excised and cultured in vitro produced AngII in superna-
tant (Figure S6D), suggesting that at least a fraction of Agt
produced by tumors may be converted into AngII locally.
Evaluating mouse and human NSCLC cell lines indicated that
tumors can produce and secrete Agt at comparable levels in
both species (Figure S6E). We also assessed Agt in 44 human
NSCLC biopsies and identified 16 specimens in which the
peptide was overexpressed (see representative samples in
Figure 6C). Thirteen of the 16 were additionally stained with
macrophage markers and all showed marked infiltration by
CD68+CD163+ TAMs (Figure S6F). CD163 expression by TAMs
suggests that these cells have tumor-promoting functions
(Biswas andMantovani, 2010). Additionally, two control biopsies
showed relatively few CD68+CD163 macrophages in unin-
volved lung tissue (Figure S6F).
To broaden our analysis, we mined publicly available informa-
tion. Analyzing 11 messenger RNA (mRNA) data sets of NSCLC-
involved and noninvolved human tissue (Oncomine database)
confirmed increased AGT expression in tumor stroma (p value:
0.0000274; Figures S6G and S6H). To evaluate whether AGT
levels in human patients might be associated with clinical
prognosis, we consulted additional databases that provide not
only tumor tissue transcriptome profiles at diagnosis but also
follow-up clinical information (Nguyen et al., 2009). Patients
were operationally separated into two cohorts according to
AGT expression: patients whose tumors expressed the highest
or lowest levels of AGT. Kaplan-Meier analysis of these two
cohorts suggested increased mortality for those whose tumors
initially showed higher AGT expression (p = 0.0552; Figure S6I).
Clinical information available for these patients is provided in
Table S1. Finally, evaluating five data sets reporting DNA copy
numbers (Oncomine database) revealed an AGT mean copy
number gain in NSCLC-involved tissue (p value: 0.038; Fig-ure S6J). Such gene amplification might contribute to Agt over-
expression in some cases and possibly confer an advantage
for disease progression. These data suggest that exploitation
of the AngII pathway by tumors is not limited to KP mice but
may also occur in a subset of human lung cancer patients.
Nonetheless, additional studies are needed to test further the
relevance of this pathway in patients.
DISCUSSION
We investigated AngII’s effects on macrophage production at
the organismal level in mice. Our findings indicate that the
hormone directly causes self-renewing HSCs and macrophage
progenitors to amplify in the spleen’s red pulp. By augmenting
these cells, the hormone helpsmaintain splenicmonocyte stores
and enables extramedullary tissue to continuously supply new
inflammatory macrophages. These results reveal AngII’s central
role in chronic inflammation mediated by macrophages.
AngII ‘‘reprograms’’ HSPC trafficking by compartmentalizing
these cells to the spleen. HSPC sequestration involves sup-
pressing S1P1-S1P signaling, according to this pathway’s
essential role in controlling leukocyte egress from peripheral
lymphoid organs (Schwab and Cyster, 2007; Massberg et al.,
2007). We did not observe AngII inducing HSPC accumulation
in lymph nodes; this is likely because homing to lymph nodes
requires CCR7, which is not expressed by HSPCs (Massberg
et al., 2007).
This study also shows that AngII-AGTR1A signaling in KPmice
amplifies TAMs. By acting on splenic HSPCs, AngII induces the
production of monocytic intermediates, which are mostly
Ly-6Chi. This subset is known to be recruited efficiently to tumors
and to carry mediators that stimulate cancer-associated
inflammation and angiogenesis (Movahedi et al., 2010; Cortez-
Retamozo et al., 2012). These findings concur with previous
observations that the renin-angiotensin systempromotes inflam-
mation and angiogenesis in the tumor stroma (George et al.,
2010) and suggest that AngII fosters these processes at least
partially by sustaining the TAM response.
HSCs express ACE (Jokubaitis et al., 2008), a peptidase that is
responsible for conversion of AngI to the principal effector AngII.
It has been proposed that ACE promotes the generation of
myeloid progenitors in an AGTR1A-dependent manner (Lin
et al., 2011) and that AGTR1A signaling controls M-CSFR
expression in HSCs (Tsubakimoto et al., 2009). Thus, AngII-AG-
TR1A signaling may not only promote HSC amplification in the
spleen, but also favor local production of mononuclear phago-
cyte lineage cells.
Whereas AngII amplifies HSPCs and monocytes in the spleen,
monocyte recruitment from circulation to tumor stroma is
thought to occur mainly via interaction between the chemokine
MCP-1 and its receptor CCR2 (Sawanobori et al., 2008;
Cortez-Retamozo et al., 2012). This suggests that mononuclear
phagocyte production and recruitment to tumors are two distinct
processes that are controlled separately. It is also likely that
mononuclear phagocytes are produced in absence of AngII
under some conditions. Identifying additional long-range
signaling pathways that control splenic HSPC amplification
and inflammatory monocyte production requires further investi-
gation. Interestingly, however, a plasma proteome profilingImmunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc. 303
Figure 5. Prolonged Reduction of AngII Production Restrains the Tumor-Promoting TAM Response and Delays Tumor Mortality in KP Mice
(A) Quantification of splenic and bone marrow-derived HSCs and MDPs in four cohorts of mice. From left to right: age-matched control mice (–cancer, n = 13),
tumor-bearing KPmice (+cancer, n = 13), KPmice treated with enalapril (+Cancer +enalapril; n = 8), and KPmice treated with hydralazine (+cancer +hydralazine;
n = 3). Tumor-bearing mice were analyzed at 11 weeks post tumor initiation. Administration of enalapril or hydralazine started at week 8.
(B) Quantification of splenic monocytes (top) and lung macrophages (bottom) in the same mice as in (A).
(C) Phenotypic characterization of lung macrophages. F4/80+ CD11cint/+ Lin macrophages (Lin defined as [B220/CD19/CD90.2/DX5/NK1.1/Ly-6G]lo) were
isolated from lungs of control mice (–cancer), tumor-bearing KPmice (+cancer) and tumor-bearing KPmice treated with enalapril (+cancer +enalapril). Mice were
analyzed at 11 weeks post tumor initiation. Treatment with enalapril started at week 8. Data show relative mRNA expression levels (real time PCR) normalized to
18 s ribosomal RNA. Analysis of Actb (Actin-b) expression was included as an internal control.
(legend continued on next page)
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Figure 6. Agt Overexpression in Mouse and
a Subset of Human NSCLC
(A) Relative AgtmRNA levels in tumor-involved and
uninvolved lung tissue of KP mice at 11–12 weeks
post tumor initiation. Lung tissue of tumor-free mice
served as control. mRNA expression is relative to
lung tissue of tumor-free mice. Each bar represents
a distinct tissue biopsy (n = 3 technical replicates
per sample).
(B) Histological detection of Agt protein in the tumor
stroma of KPmice at 11 weeks post tumor initiation.
Center shows full view of the lung lobe; top shows
higher magnification image of uninvolved tissue;
bottom shows highermagnification image of tumor-
involved tissue. Data are representative of four
mice. Scale bar represents 50 mm.
(C) Representative examples of detectable AGT
protein expression (patient 7D4) or absence thereof
(patient 8B4) in lung biopsy specimens from a total
of 44 patients with stage 1 NSCLC. AGT staining
was scored from 0 to 200 as described in Supple-
mental Experimental Procedures (scores for patient
8B4 is 0 and for patient 7D4 is 95). Scale bar
represents 50 mm. Known genetic alterations
(KRAS) are indicated.
Data in (A) are presented as mean ± SEM. See also
Figure S6 and Table S1.
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models of cancer, including NSCLC driven by KRAS or EGFR
(Taguchi et al., 2011), suggesting that diverse cancer types
can activate the AngII pathway.
How do mouse and human hematopoietic responses
compare? Because lung cancer patients’ spleens are typically
neither removed nor biopsied, we could not assess whether
this type of cancer triggers splenic HSPC amplification in
humans. Nevertheless, ex vivo analysis of splenic tissue from
patients with pancreatic ductal adenocarcinoma indicates not
only that human tumors promote extramedullary monocyte
production but also that the magnitude of this activity is compa-
rable in humans and mice when scale differences between
species are taken into account (Cortez-Retamozo et al., 2012).
Similar splenic HSPC responses have been observed in patients
with cardiovascular diseases (Dutta et al., 2012). However, the(D) Number (top) and total volume (bottom) of lung tumors detected by high resolution CT at 11 weeks post t
that started a treatment with enalapril or hydralazine at week 8.
(E) Representative 3D volume renderings of tumors at week 11 (Wk 11) from mice treated (right) or not (left
shown in red, lungs in green, and bones in yellow.
(F) Kaplan-Meier survival analysis of KP mice treated (n = 12) or not (n = 14) with enalapril starting at week
Data in (A) (B) and (D) are presented as median with dots indicating measurements for single mice. Data in (C
***p < 0.001; ns, nonsignificant. See also Figure S5.
Immunity 38, 296–308extent to which the human spleen contrib-
utes TAMs, and whether ACEi treatment
controls extramedullary monocytopoiesis
in cancer patients, requires study. Molec-
ular imaging technologies that assess bio-
logical processes noninvasively in patients
are being developed (Weissleder and
Pittet, 2008), and such advances may beused to evaluate the extramedullary macrophage progenitor
response in NSCLC or other cancers.
As detailed above, ACEi treatment suppresses TAM progen-
itor amplification and increases survival in tumor-bearing KP
mice. The efficacy of such treatment in at least some human
patients requires investigation. Interestingly, a retrospective
study by Lever et al. hypothesized that long-term ACEi treatment
protects against human cancer based on decreased risk of both
incidence of and fatality from lung and breast cancers (Lever
et al., 1998). The risk of cancer did not decrease in patients
receiving other classes of antihypertensive drugs. These results
agree with our findings that antitumor effects mediated by ACEi
depend on mechanisms other than those controlling blood
pressure.
Several retrospective evaluations of ACEi or AngII receptor
blocker (ARB) treatment on cancer incidence provide differentumor initiation in KPmice. The legend identifies mice
) with enalapril for 3 consecutive weeks. Tumors are
s 8 post tumor initiation.
) are presented as mean ± SEM. *p < 0.05; **p < 0.01;
, February 21, 2013 ª2013 Elsevier Inc. 305
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cancer in those receiving ACEi (Lang, 2006). By contrast, another
study suggested increased incidence of cancer in patients
receiving ARBs (Sipahi et al., 2010), though two subsequent
investigations questioned this result and concluded that ACEi
and ARB alone neither increases nor decreases cancer inci-
dence (Bangalore et al., 2011) or that ARBs may prevent cancer
development (Huang et al., 2011). In addition, it remains to be
determined whether ACEi or ARB therapy may benefit patients
with established cancer. Addressing these questions requires
testing in prospective human clinical trials.
The present study implies that such human trials should
consider NSCLCpatients in whom the AngII pathway is elevated.
On the basis of increasing evidence that the immune system
contributes to cancer progression, research should focus on
drug combinations that not only efficiently kill cancer cells but
also shape the immune system in a way that is favorable to the
host (Zitvogel et al., 2008). ACEi could be used to reduce TAM
production in patients that overexpress AngII, whereas other
coadministered agents would target tumor cells and possibly
other host cell components. A retrospective study of NSCLC
patients undergoing first-line platinum-based therapy suggests
that either ACEi or ARB therapy may increase survival, yet the
survival advantage could not be attributed to other established
risk factors (Wilop et al., 2009).
Considering the complex nature of RAS signaling (George
et al., 2010), it is possible that distinct therapeutics such as
ACEi and ARBs mediate divergent effects on the hematopoietic
response. Future studies should compare these two drugs’
effects on HSC and macrophage production in vivo. It will also
be important to consider tumor resistance to ACEi or ARBs
following extended treatment, a process that can already be
investigated in animal models.
In conclusion, we show that AngII has a profound impact on
the macrophage response, that this mechanism fosters cancer
growth in KP mice, and that blocking AngII production can
restrain macrophage amplification. These data also have
important experimental and therapeutic implications that go
beyond cancer. For instance, extramedullary HSPC amplifica-
tion governs the macrophage response in experimental myocar-
dial infarction (Leuschner et al., 2012) and atherosclerosis
(Robbins et al., 2012), two inflammatory conditions associated
with increased AngII activity in humans (McAlpine and Cobbe,
1988; Schieffer et al., 2000). Future studies should thus explore
AngII’s capacity to amplify macrophage production in various
clinical settings.EXPERIMENTAL PROCEDURES
Animals and Tumor Models
KrasLSL-G12D/+;p53fl/fl (referred to as KP) mice in a 129 background were used
as a conditional mouse model of NSCLC and described previously (Cortez-
Retamozo et al., 2012). To induce lung adenocarcinoma, KP mice were
infected with an adenovirus expressing Cre recombinase (AdCre) by intranasal
instillation, as described previously (DuPage et al., 2009). AdCre was
purchased from the University of Iowa Gene Transfer Vector Core. For parabi-
osis and spleen transplant experiments, a murine NSCLC cell line isolated
from tumor nodules of KP mice and injected intravenously to induce lung
adenocarcinoma. Usually, we injected 0.5–1 3 105 tumor cells and mice
were analyzed 6–7 week post injection.306 Immunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc.(ACTB-eYFP)7AC5Nagy/J (referred to as EYFP) mice in a 129 background
were a gift from Dr. Andras Nagy, Mount Sinai Hospital, Toronto, Canada.
Agtr1a–/– B6.129P2-Agtr1atm1Unc/J (referred to as Agtr1a –/–) mice, C57BL/
6-Tg (UBC-GFP)30Scha/J (referred to as GFP) mice, B6.SJL-Ptprca Pepcb/
BoyJ (referred to as CD45.1) mice, C57BL/6 mice and 129 mice were bought
from The Jackson Laboratory. All animal experiments were approved by the
Massachusetts General Hospital Subcommittee on Research Animal Care.
Flow Cytometry and Cell Sorting
Information about the antibodies used in the study (clone number and vendor)
is listed in Supplemental Information. The number of monocytes/macro-
phages, progenitor, and other cells was defined as the total number of cells
per organ multiplied by the percentage of each cell type identified by flow
cytometry (LSRII; BD Biosciences). Data were analyzed with FlowJo v.8.8.7
(Tree Star, Inc.). For adoptive transfer experiments, cell suspensions obtained
from the spleen or the bone marrow were stained with appropriate antibodies;
cells of interest were sorted (FACS Aria, BD Biosciences) and injected intrave-
nously without delay. Typically, 0.3–1 3 105 HSC were injected.
Histology
For histological analysis, mouse lung tissue was harvested, fixed in 10%
formalin solution, and embedded in paraffin. Serial paraffin-embedded
sections were prepared and the tissue sections were stained with hematoxylin
and eosin (H&E) (Sigma Aldrich). Paraffin embedded lung sections from 44
patients with stage 1 lung adenocarcinoma were obtained at Massachusetts
General Hospital. A detailed protocol for detection of Agt, CD68, and CD162
in lung tissue is included in Supplemental Information. All stained human tissue
sections were analyzed independently by two trained lung pathologists. Agt
staining was scored from 0 to 200 (200 is equivalent to high Agt staining in
100% of tumor cells; 100 is equivalent to high Agt staining in 50% of tumor
cells or intermediate staining in 100% of tumor; 0 is equivalent to undetectable
Agt staining). Final score for a sample was defined as the mean of the two
scores given by the pathologists. The threshold value used to identify samples
that overexpress AGT was 50, which is equivalent to high staining in 25% of
tumor cells or intermediate staining in 50% of tumor cells.
Intravital Microscopy
Wild-type or Agtr1a–/– GFP+ HSC cells were adoptively transferred to Ang
II-treated mice and visualized in the spleen 7 days later by using an Olympus
FV1000 confocal laser scanning system on an upright BX61-WI microscope
running the Fluoview 1000 version 2.1 software (Olympus). For imaging, the
mice were placed onto a temperature-regulated heating plate (Olympus
Corporation Tokyo, JP) set to 38C. The spleen was exposed surgically and
kept moist during imaging as previously described (Swirski et al., 2009). A
20X Olympus objective (Uplan FL N, NA 0.5) was used for imaging with fields
of view of 535 mm.Cells expressing GFP and blood vessels labeledwith Angio-
Sense-680 (ViSen Medical-Perkin Elmer) were visualized through excitation at
488 nm and 635 nm, also as previously described (Swirski et al., 2009).
Noninvasive Evaluation of Tumor Burden by High Resolution CT
Mice infected with AdCre, and treated or not with ACEi, were anonymized,
subjected to high-resolution CT at different time points, and analyzed blindly
by a radiologist. Mice were anesthetized with isoflurane gas inhalation. They
also had a respiratory pillow placed underneath the abdomen to provide gating
of X-ray exposures on expiration of the respiratory cycle and thus to prevent
motion artifacts. The CT data were acquired on an Inveon PET-CT system
(Siemens; isotropic spatial resolution: 50 mm). For CT imaging, Isovue-370
(Bracco Diagnostics) was infused intravenously at 55 ml/min through a tail
vein catheter to increase vascular contrast. For data analysis, multiplanar
and 3D reconstructions were obtained by using OsiriX (The OsiriX foundation)
and AMIRA (Visage Imaging, Inc.). Tumor number and volume were
segmented and measured by two board-certified radiologists who were
blinded to the treatment groups and to each other’s measurements.
Quantitative Real-Time PCR
Tissue samples were collected into RNA later solution (Ambion). Homogeniza-
tion was performed in RLT lysis buffer (QIAGEN) supplemented with 1%
2-mercaptoethanol by using a glass dounce tissue homogenizer. For FACS
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(350 ml RLT/1 3 105 cells). RNA extraction was performed without delay by
using the QIAGEN RNAeasy mini or micro kits (QIAGEN). Complementary
DNA was prepared by using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). The primers and probes that were used are
described in Supplemental Information.
Statistics
Statistical tests included unpaired, two-tailed Student’s t test and one-way
ANOVA followed by Tukey’s multiple comparison test (for more than two
groups). For data not normally distributed, we applied the nonparametric
Krustal-Wallis test followed by the Dunn’s multiple comparison test. For
survival studies, we applied the Mantel-Cox test. Demographic and clinical
characteristics of patients were analyzed by means of the Fisher’s exact
test, chi-square and unpaired two-tailed Student’s t test. P values < 0.05
were considered to denote significance.
Additional experimental procedures are included in Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2012.10.015.
ACKNOWLEDGMENTS
The authors thank Jessica Truelove (MGH) for imaging and Michael Waring
and Adam Chicoine (Ragon Institute, MGH) for sorting cells. This work was
supported in part by NIH grants P50-CA86355, R01-AI084880, R56-
AI084880, and MGH-Center for Systems Biology (to M.J.P.) and U54-
CA126515 (to R.W.). M.E. is part of the International PhD program ‘‘Cancer
and Immunology’’ at the University of Lausanne, Switzerland, and was sup-
ported by the AACR Centennial Predoctoral Fellowship and the Boehringer
Ingelheim Fonds.
Received: July 17, 2012
Accepted: October 2, 2012
Published: January 17, 2013
REFERENCES
AbdAlla, S., Lother, H., Langer, A., el Faramawy, Y., and Quitterer, U. (2004).
Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes
at the onset of atherosclerosis. Cell 119, 343–354.
Bangalore, S., Kumar, S., Kjeldsen, S.E., Makani, H., Grossman, E.,
Wetterslev, J., Gupta, A.K., Sever, P.S., Gluud, C., and Messerli, F.H. (2011).
Antihypertensive drugs and risk of cancer: network meta-analyses and trial
sequential analyses of 324,168 participants from randomised trials. Lancet
Oncol. 12, 65–82.
Biswas, S.K., and Mantovani, A. (2010). Macrophage plasticity and interaction
with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896.
Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P.J., Chudnovskiy, A.,
Berger, C., Ryan, R.J., Iwamoto, Y., Marinelli, B., Gorbatov, R., et al. (2012).
Origins of tumor-associated macrophages and neutrophils. Proc. Natl.
Acad. Sci. USA 109, 2491–2496.
De Palma, M., Murdoch, C., Venneri, M.A., Naldini, L., and Lewis, C.E. (2007).
Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic
implications. Trends Immunol. 28, 519–524.
DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden,
S.F., Gallagher, W.M., Wadhwani, N., Keil, S.D., Junaid, S.A., et al. (2011).
Leukocyte complexity predicts breast cancer survival and functionally regu-
lates response to chemotherapy. Cancer Discov 1, 54–67.
DuPage,M., Dooley, A.L., and Jacks, T. (2009). Conditional mouse lung cancer
models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc.
4, 1064–1072.Dutta, P., Courties, G., Wei, Y., Leuschner, F., Gorbatov, R., Robbins, C.S.,
Iwamoto, Y., Thompson, B., Carlson, A.L., Heidt, T., et al. (2012). Myocardial
infarction accelerates atherosclerosis. Nature 487, 325–329.
Fogg, D.K., Sibon, C., Miled, C., Jung, S., Aucouturier, P., Littman, D.R.,
Cumano, A., and Geissmann, F. (2006). A clonogenic bone marrow progenitor
specific for macrophages and dendritic cells. Science 311, 83–87.
Freedman, M.H., and Saunders, E.F. (1981). Hematopoiesis in the human
spleen. Am. J. Hematol. 11, 271–275.
Gabrilovich, D.I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated
regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268.
Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., and Ley, K.
(2010). Development of monocytes, macrophages, and dendritic cells.
Science 327, 656–661.
George, A.J., Thomas, W.G., and Hannan, R.D. (2010). The renin-angiotensin
system and cancer: old dog, new tricks. Nat. Rev. Cancer 10, 745–759.
Goodman, J.W., and Hodgson, G.S. (1962). Evidence for stem cells in the
peripheral blood of mice. Blood 19, 702–714.
Grivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation,
and cancer. Cell 140, 883–899.
Hanahan, D., and Coussens, L.M. (2012). Accessories to the crime: functions
of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322.
Huang, C.C., Chan, W.L., Chen, Y.C., Chen, T.J., Lin, S.J., Chen, J.W., and
Leu, H.B. (2011). Angiotensin II receptor blockers and risk of cancer in patients
with systemic hypertension. Am. J. Cardiol. 107, 1028–1033.
Jokubaitis, V.J., Sinka, L., Driessen, R., Whitty, G., Haylock, D.N., Bertoncello,
I., Smith, I., Pe´ault, B., Tavian, M., and Simmons, P.J. (2008). Angiotensin-con-
verting enzyme (CD143) marks hematopoietic stem cells in human embryonic,
fetal, and adult hematopoietic tissues. Blood 111, 4055–4063.
Landsman, L., Varol, C., and Jung, S. (2007). Distinct differentiation potential of
blood monocyte subsets in the lung. J. Immunol. 178, 2000–2007.
Lang, L. (2006). ACE inhibitors may reduce esophageal cancer incidence.
Gastroenterology 131, 343–344.
Lanz, T.V., Ding, Z., Ho, P.P., Luo, J., Agrawal, A.N., Srinagesh, H., Axtell, R.,
Zhang, H., Platten, M., Wyss-Coray, T., and Steinman, L. (2010). Angiotensin II
sustains brain inflammation in mice via TGF-beta. J. Clin. Invest. 120, 2782–
2794.
Leuschner, F., Panizzi, P., Chico-Calero, I., Lee, W.W., Ueno, T., Cortez-
Retamozo, V., Waterman, P., Gorbatov, R., Marinelli, B., Iwamoto, Y., et al.
(2010). Angiotensin-converting enzyme inhibition prevents the release of
monocytes from their splenic reservoir in mice with myocardial infarction.
Circ. Res. 107, 1364–1373.
Leuschner, F., Rauch, P.J., Ueno, T., Gorbatov, R., Marinelli, B., Lee, W.W.,
Dutta, P., Wei, Y., Robbins, C., Iwamoto, Y., et al. (2012). Rapid monocyte
kinetics in acute myocardial infarction are sustained by extramedullary mono-
cytopoiesis. J. Exp. Med. 209, 123–137.
Lever, A.F., Hole, D.J., Gillis, C.R., McCallum, I.R., McInnes, G.T., MacKinnon,
P.L., Meredith, P.A., Murray, L.S., Reid, J.L., and Robertson, J.W. (1998). Do
inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
Lancet 352, 179–184.
Lin, C., Datta, V., Okwan-Duodu, D., Chen, X., Fuchs, S., Alsabeh, R., Billet, S.,
Bernstein, K.E., and Shen, X.Z. (2011). Angiotensin-converting enzyme is
required for normal myelopoiesis. FASEB J. 25, 1145–1155.
Liu, K., Waskow, C., Liu, X., Yao, K., Hoh, J., and Nussenzweig, M. (2007).
Origin of dendritic cells in peripheral lymphoid organs of mice. Nat.
Immunol. 8, 578–583.
Ma, F., Li, Y., Jia, L., Han, Y., Cheng, J., Li, H., Qi, Y., and Du, J. (2012).
Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for
TGF b/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS
ONE 7, e35144.
Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related
inflammation. Nature 454, 436–444.
Massberg, S., Schaerli, P., Knezevic-Maramica, I., Ko¨llnberger, M., Tubo, N.,
Moseman, E.A., Huff, I.V., Junt, T., Wagers, A.J., Mazo, I.B., and von Andrian,Immunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc. 307
Immunity
Macrophage Production Mediated by Angiotensin IIU.H. (2007). Immunosurveillance by hematopoietic progenitor cells trafficking
through blood, lymph, and peripheral tissues. Cell 131, 994–1008.
McAlpine, H.M., and Cobbe, S.M. (1988). Neuroendocrine changes in acute
myocardial infarction. Am. J. Med. 84(3A), 61–66.
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange´, G., Van den
Bossche, J., Mack, M., Pipeleers, D., In’t Veld, P., De Baetselier, P., and Van
Ginderachter, J.A. (2010). Different tumor microenvironments contain func-
tionally distinct subsets of macrophages derived from Ly6C(high) monocytes.
Cancer Res. 70, 5728–5739.
Nguyen, D.X., Chiang, A.C., Zhang, X.H., Kim, J.Y., Kris, M.G., Ladanyi, M.,
Gerald, W.L., and Massague´, J. (2009). WNT/TCF signaling through LEF1
and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51–62.
Pittet, M.J., and Weissleder, R. (2011). Intravital imaging. Cell 147, 983–991.
Qian, B.Z., and Pollard, J.W. (2010). Macrophage diversity enhances tumor
progression and metastasis. Cell 141, 39–51.
Robbins, C.S., Chudnovskiy, A., Rauch, P.J., Figueiredo, J.L., Iwamoto, Y.,
Gorbatov, R., Etzrodt, M., Weber, G.F., Ueno, T., van Rooijen, N., et al.
(2012). Extramedullary hematopoiesis generates Ly-6C(high) monocytes that
infiltrate atherosclerotic lesions. Circulation 125, 364–374.
Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J.E., Abe, J.,
Shono, Y., Kitabatake,M., Kakimi, K., Mukaida, N., andMatsushima, K. (2008).
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in
tumor-bearing mice. Blood 111, 5457–5466.
Schieffer, B., Schieffer, E., Hilfiker-Kleiner, D., Hilfiker, A., Kovanen, P.T.,
Kaartinen, M., Nussberger, J., Harringer, W., and Drexler, H. (2000).
Expression of angiotensin II and interleukin 6 in human coronary atheroscle-
rotic plaques: potential implications for inflammation and plaque instability.
Circulation 101, 1372–1378.
Schulz, C., Gomez Perdiguero, E., Chorro, L., Szabo-Rogers, H., Cagnard, N.,
Kierdorf, K., Prinz, M., Wu, B., Jacobsen, S.E., Pollard, J.W., et al. (2012). A
lineage of myeloid cells independent of Myb and hematopoietic stem cells.
Science 336, 86–90.
Schwab, S.R., and Cyster, J.G. (2007). Finding a way out: lymphocyte egress
from lymphoid organs. Nat. Immunol. 8, 1295–1301.
Shi, C., and Pamer, E.G. (2011). Monocyte recruitment during infection and
inflammation. Nat. Rev. Immunol. 11, 762–774.
Sipahi, I., Debanne, S.M., Rowland, D.Y., Simon, D.I., and Fang, J.C. (2010).
Angiotensin-receptor blockade and risk of cancer: meta-analysis of rando-
mised controlled trials. Lancet Oncol. 11, 627–636.
Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A.,
Jones, S.J., Iqbal, J., Weisenburger, D.D., et al. (2010). Tumor-associated308 Immunity 38, 296–308, February 21, 2013 ª2013 Elsevier Inc.macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med.
362, 875–885.
Swirski, F.K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo,
V., Panizzi, P., Figueiredo, J.L., Kohler, R.H., Chudnovskiy, A., Waterman, P.,
et al. (2009). Identification of splenic reservoir monocytes and their deployment
to inflammatory sites. Science 325, 612–616.
Taguchi, A., Politi, K., Pitteri, S.J., Lockwood, W.W., Fac¸a, V.M., Kelly-Spratt,
K., Wong, C.H., Zhang, Q., Chin, A., Park, K.S., et al. (2011). Lung cancer
signatures in plasma based on proteome profiling of mouse tumor models.
Cancer Cell 20, 289–299.
Tsubakimoto, Y., Yamada, H., Yokoi, H., Kishida, S., Takata, H., Kawahito, H.,
Matsui, A., Urao, N., Nozawa, Y., Hirai, H., et al. (2009). Bone marrow angio-
tensin AT1 receptor regulates differentiation of monocyte lineage progenitors
from hematopoietic stem cells. Arterioscler. Thromb. Vasc. Biol. 29, 1529–
1536.
Ugel, S., Peranzoni, E., Desantis, G., Chioda, M., Walter, S., Weinschenk, T.,
Ochando, J.C., Cabrelle, A., Mandruzzato, S., and Bronte, V. (2012).
Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment
of the Spleen. Cell Rep. 2, 628–639.
van Furth, R., and Cohn, Z.A. (1968). The origin and kinetics of mononuclear
phagocytes. J. Exp. Med. 128, 415–435.
Weissleder, R., and Pittet, M.J. (2008). Imaging in the era of molecular
oncology. Nature 452, 580–589.
Wilop, S., vonHobe, S., Crysandt,M., Esser, A., Osieka, R., and Jost, E. (2009).
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1
receptor blockers on survival in patients with advanced non-small-cell lung
cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res.
Clin. Oncol. 135, 1429–1435.
Wright, D.E., Wagers, A.J., Gulati, A.P., Johnson, F.L., and Weissman, I.L.
(2001). Physiological migration of hematopoietic stem and progenitor cells.
Science 294, 1933–1936.
Zhang, B., Yao, G., Zhang, Y., Gao, J., Yang, B., Rao, Z., and Gao, J. (2011a).
M2-polarized tumor-associated macrophages are associated with poor prog-
noses resulting from accelerated lymphangiogenesis in lung adenocarcinoma.
Clinics (Sao Paulo) 66, 1879–1886.
Zhang, B.C., Gao, J., Wang, J., Rao, Z.G., Wang, B.C., and Gao, J.F. (2011b).
Tumor-associated macrophages infiltration is associated with peritumoral
lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med.
Oncol. 28, 1447–1452.
Zitvogel, L., Apetoh, L., Ghiringhelli, F., and Kroemer, G. (2008). Immunological
aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73.
